Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer

This phase II multicenter, randomized study evaluates the safety and efficacy of neoadjuvant short-course radiotherapy (SCRT) sequentially combined with AK112 (Envafolimab) with or without chemotherapy in patients with locally advanced rectal cancer (LARC). The study also aims to identify biomarkers predicting tumor response and develop efficacy prediction models.

Trial Details

NCT ID
NCT06718543
Phase
PHASE2
Sponsor
fan li
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • AK112 with SCRT and CapeOX
  • AK112 with SCRT
Locations (sample)
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771

Key Eligibility Criteria

  • Signed written informed consent.
  • Age 18-80 years, male or female.
  • Histologically confirmed rectal adenocarcinoma.
  • Clinical baseline stage T3-4NxM0 or TxN1-2M0 by MRI assessment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →